foe st.
kowsuis  ¢. lof 2
ee . °
JUN - 5 2009
510(k) Summary for the PEAK PlasmaBlade™ TnA Tonsil and
Adenoid Tissue Dissection Device
‘L Submitter name and address: ,
PEAK Surgical, Inc.
2464 Embarcadero Way
Palo Alto, CA 94303
Phone: 650-331-3020
Fax: 650-331-3293 .
Contact: Lois Nakayama
Date Prepared: June 5, 2009
2. Device Name:
Trade Name: PEAK PlasmaBlade™ TnA Tonsil and Adenoid Tissue
Dissection Device
Common Name: Electrosurgical Device and Accessories
Classification Name: Electrosurgical Cutting and Coagulation Device and
Accessories (21 CFR 878.4400)
3. Predicate Devices: :
PEAK PlasmaBlade™ Tissue Dissection Device (K073057)
ArthroCare® ENT Plasma Wands™ (K070374)
4. Device description:
The PEAK PlasmaBlade TnA Tonsil and Adenoid Tissue Dissection Device
consists of a handpiece with integrated controls and cable, a shaft with a suction
cannula, and two interchangeable tips. The tonsil tip consists of a curved and
tapered insulated blade electrode with an opening in the center to allow for the
evacuation of smoke and fluids. The adenoid tip consists of a flat, straight
insulated blade electrode housed in a plastic tip with a bendable suction lumen
: that allows for the evacuation of tissue, fluids and smoke. Both tips connect to
the suction cannula of the handpiece. : /
5. Intended Use: ,
The PEAK PlasmaBlade TnA Tonsil and Adenoid Tissue Dissection Device is :
only intended to be used for the cutting and coagulation of soft tissue during
otolaryngology (ENT) surgery including adenoidectomy and tonsillectomy .
(Pharyngeal, Tubal, Palatine).
PEAK Surgical, Inc. : ‘ 20
510(k) Notification for PEAK PlasmaBlade TnA : .
Raviead tune & 20Na .

Kot aus paPete |
6. Technological Characteristics: /
The PEAK PlasmaBlade TnA Tonsil and Adenoid Tissue Dissection Device is
: . similar to the predicate devices in that they are all electrosurgical instruments ;
used to cut tissue and coagulate soft tissue; utilizing RF powered distal ends.
Te Performance Data: vs
Preclinical laboratory and performance tests were executed to ensure the device —
: functioned as-intended and met design specifications. Sufficient data were
obtained to show that the device is substantially equivalent to the predicate
devices, and meets safety and effectiveness criteria.
8. Sterilization: .
The PEAK PlasmaBlade TnA Tonsil and Adenoid Tissue Dissection Device is
provided sterile. The device is not intended for reuse or resterilization.
9... Conclusions:
By virtue of design, materials, function, and intended use, the PEAK PlasmaBlade
TnA Tonsil and Adenoid Tissue Dissection Device is substantially equivalent to
FDA-cleared devices currently marketed in the United States. In establishing ;
substantial equivalence to the predicate devices, PEAK Surgical evaluated the
indications for use, materials incorporated, product specification and energy
requirements of those systems.
PEAK Surgical, Inc. 21
510(k) Notification for PEAK PlasmaBlade TnA - .
Revieed Lina & 20NG

2 ¢ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
(ns Food and Drug Administration
9200 Corporate Boulevard
JUN - 5 2009 Rockville MD 20850
PEAK Surgical, Incorporated
% Ms. Lois Nakayama .
Manager, Regulatory Affairs
2464 Embarcadero Way
Palo Alto, California 94303
: Re: K083415
Trade/Device Name: PEAK PlasmaBlade™ TnA Tonsil And Adenoid Tissue
_ Dissection Device
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting And Coagulation Device And Accessories
Regulatory Class: II
Product Code: GEI
~~ Dated: June Ty 2000
/ Received: June 3, 2009
Dear Ms. Nakayama:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the
indications for use stated in the enclosure) to legally marketed predicate devices marketed in
interstate commerce prior to May 28, 1976, the enactment date of the Medical Device .
Amendments, or to devices that have been reclassified in accordance with the provisions of
the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket
approval application (PMA). You may, therefore, market the device, subject to the general
.controls provisions of the Act. The general controls provisions of the Act include
requirements for annual registration, listing of devices, good manufacturing practice,
labeling, and prohibitions against misbranding and adulteration. /
If your device is classified (see above) into either class II (Special Controls) or class III
(PMA), it may be subject to additional controls. Existing major regulations affecting your
device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In
addition, FDA may publish further announcements concerning your device in the Federal
Register. ;
Please be advised that FDA’s issuance of a substantial equivalence determination does not
mean that FDA has made a determination that your device complies with other requirements
of the Act or any Federal statutes and regulations administered by other Federal agencies.
. You must comply with all the Act’s requirements, including, but not limited to: registration
and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting

Page 2-Ms. Lois Nakayama
_ (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing
practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
and if applicable, the electronic product radiation control provisions (Sections 531-542 of
. the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801),
please go to
_ http://www.fda.gow/AboutFDA/CentersOffices/CDRH/ CDRHOffices/ucm115809.htm for
the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also,
please note the regulation entitled, "Misbranding by reference to premarket notification”
(21CFR Part 807.97). For questions regarding the reporting of adverse events under the
MDR regulation (21 CFR Part 803), please go to http://www. fda.gow/cdrh/mdr/ for the
CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free
FM EF (800) 638-2041 oF (240) 276-3150 or at its Internet address
http://www.fda.gov/cdrh/industry/support/index.html.
: . Sincerely yours, {
: | wi
a f- he (ll, a
Mark N. Melkerson ))
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and Radiological Health
Enclosure , . oo
\

1.08 3° 1S oF I
oO
Indications for Use
510(k) Number (if known): K083415
. Device Name: PEAK:PlasmaBlade™ TnA Tonsil and Adenoid Tissue Dissection :
- Device
‘ Indications for Use:
The PEAK PlasmaBlade™ TnA Tonsil and Adenoid Tissue Dissection Device is only .
a indicated for cutting and coagulation of soft tissue during otolaryngology (ENT) surgery
including adenoidectomy and tonsillectomy (Pharyngeal, Tubal, Palatine)..
: Prescription Use _ X AND/OR Over-The-Counter Use
, (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
/ IF NEEDED)
: Concurrapag of ROY ong of Device Evaluation (ODE)
(Division Sign-Off) ,
Division of Surgical; Orthopedic,
, : and Restorative Devices
— $10(k) Number. KOs 4is~ . oe

